China adds Dupilumab to national drug catalog for four indications
The national medical insurance drug catalog was recently announced, and the drug Dupilumab has been added to it for the first time for four indications. The drug is approved for moderate to severe atopic dermatitis in infants aged 6 months and older and adults, and it is also approved for asthma in children aged 6 and older and adults, chronic obstructive pulmonary disease in adults, nodular prurigo, and bullous pemphigoid.
What Dupilumab targets
Dupilumab is a biologic agent that targets interleukin-4 and interleukin-13. These proteins are involved in type 2 inflammation. The drug's inclusion in the national medical insurance catalog improves patient accessibility and supports adherence to standard treatment.
COPD and asthma
Approximately 100 million people in China have chronic obstructive pulmonary disease. About 40% of COPD patients have type 2 inflammation characterized by elevated eosinophils. This type 2 inflammation increases the risk of acute exacerbations.
Type 2 inflammation is also a key factor in asthma exacerbations and recurrence. Chen Rongchang, a professor at Guangzhou Medical University Affiliated First Hospital, said that COPD and asthma control remain challenging for common chronic airway diseases, and Dupilumab offers a new option for improving symptoms and lung function.
Atopic dermatitis and bullous pemphigoid
The estimated number of atopic dermatitis patients in China exceeds 80 million. The drug is approved for infants aged 6 months and older, addressing a gap in the treatment of young infants. Zhang Jianzhong, a professor at Peking University People's Hospital, said that atopic dermatitis is a common chronic inflammatory skin disease, and Dupilumab's approval for infants aged 6 months and older addresses a gap in treating young infants.
For bullous pemphigoid, the drug helps reduce the burden on elderly patients and supports standardized, precise treatment. Zhang Furén, a professor at Shandong First Medical University Affiliated Dermatology Hospital, said that for bullous pemphigoid, the drug helps reduce the burden on elderly patients and supports standardized, precise treatment.
What the drug does
Gao Xinghua, a professor at China Medical University Affiliated First Hospital, said that chronic inflammatory skin diseases have historically focused on symptomatic treatment, but Dupilumab promotes a shift toward targeted, cause-based treatment. Qu Jieming, a professor at Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, said that the drug's inclusion in the national medical insurance catalog improves patient accessibility and helps patients adhere to standard treatment.
Glossary
- Dupilumab — Dupilumab is a biologic agent that targets interleukin-4 and interleukin-13. These proteins are involved in type 2 inflammation. The drug's inclusion in the national medical insurance catalog improves patient accessibility and supports adherence to standard treatment.
- atopic dermatitis — Atopic dermatitis is a common chronic inflammatory skin disease. The estimated number of atopic dermatitis patients in China exceeds 80 million. The drug is approved for infants aged 6 months and older, addressing a gap in the treatment of young infants.
- interleukin-4 — The drug Dupilumab targets interleukin-4 and interleukin-13. These proteins are involved in type 2 inflammation.
- interleukin-13 — The drug Dupilumab targets interleukin-4 and interleukin-13. These proteins are involved in type 2 inflammation.
- type 2 inflammation — Type 2 inflammation is a key factor in asthma exacerbations and recurrence. About 40% of COPD patients have type 2 inflammation characterized by elevated eosinophils.
This article was written with AI assistance from multiple news reports and is reviewed by our editors under our editorial principles. Editorial Standards · Tips & Contact
Comments 0